title: Psychopharmacological treatment among adolescents with disabilities: Prevalence and predictors in a nationally representative sample.
abstract: Little is known about psychopharmacological treatment among adolescents with educational disabilities. This study (a) describes pharmacotherapy among adolescents who received special education, and (b) examines the relations to adolescents' disability type and sociodemographic characteristics. The sample was 9,230 adolescents who participated in the National Longitudinal Transition Study 2, a nationally representative study of students with disabilities. Descriptive statistics and logistic regression were used to estimate prevalence and predictors of pharmacotherapy. During the study period, 18.14% of adolescents received pharmacotherapy with 11.75% receiving monopharmacy, 6.39% receiving polypharmacy, and 5.86% simultaneously receiving multiple classes of medications. Stimulants and antidepressants were the most commonly used classes of psychotropic medication. After adjusting for sociodemographics, pharmacotherapy was highest among adolescents with other health impairments, emotional disturbance, and autism. Disability type, race/ethnicity, marital status, head of household education, urbanicity, and private insurance type were significant predictors of polypharmacy. Overall, these results indicated rates of psychopharmacological treatment exceeded those in the general population and disparities across sociodemographic groups existed. Implications for research and practice are discussed.
authors.affiliation: Department of Educational Psychology and Special Education, College of Education & Human Development, University of Minnesota.
authors.forename: Amanda L
authors.initials: AL
authors.lastname: Sullivan
authors.affiliation: Department of Educational Psychology and Special Education, College of Education & Human Development, University of Minnesota.
authors.forename: Shanna
authors.initials: S
authors.lastname: Sadeh
mesh_terms: D000293:Adolescent; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001321:Autistic Disorder / Q000188:drug therapy; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy; D006233:Persons with Disabilities / Q000193:education* / Q000534:rehabilitation / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D004519:Education, Special; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy / Q000453:epidemiology; D007859:Learning Disabilities / Q000188:drug therapy / Q000453:epidemiology; D008137:Longitudinal Studies
chemical_list: D000928:Antidepressive Agents; D000697:Central Nervous System Stimulants